Muscarinic M₁ agonists in the treatment of Alzheimer’s disease

By Korczyn A.D.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 10, 2000-10 ,pp. : 2259-2267

Informa Healthcare

Access to resources Recommend Favorite

Muscarinic Receptor Agonists in Alzheimer's Disease: More Than Just Symptomatic Treatment?

By Fisher A.  

CNS Drugs, Vol. 12, Iss. 3, 1999-09 ,pp. : 197-214

Adis International

Access to resources Recommend Favorite

Muscarinic Receptor Agonists and Antagonists in the Treatment of Alzheimer's Disease

By  

Current Pharmaceutical Design, Vol. 11, Iss. 26, 2005-10 ,pp. : 3353-3361

Bentham Science Publishers

Access to resources Recommend Favorite

Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M 1 receptors

By Messer W.S.   Rajeswaran W.G.   Cao Y.   Zhang H.-J.   El-Assadi A.A.   Dockery C.   Liske J.   O'Brien J.   Williams F.E.   Huang X.-P.   Wroblewski M.E.   Nagy P.I.   Peseckis S.M.  

Pharmaceutica Acta Helvetiae, Vol. 74, Iss. 2, 2000-03 ,pp. : 135-140

Elsevier

Access to resources Recommend Favorite

Muscarinic M1 receptor agonists and M2 receptor antagonists as therapeutic targets in Alzheimer’s disease

By Sheardown Malcolm J  

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 6, 2002-06 ,pp. : 863-870

Informa Healthcare

Access to resources Recommend Favorite